OVID
Live chart
What they do
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies.
For information only · Important disclosures
Grades vs sector
No sector grades for OVID yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | -0.10 | -0.08 | +23.3% |
| 2026-05-12 | -0.11 | -0.12 | -13.2% |
| 2026-03-18 | -0.10 | 0.06 | +161.2% |
| 2025-11-12 | -0.15 | -0.17 | -14.9% |
| 2025-08-13 | -0.15 | -0.06 | +59.3% |
| 2025-05-13 | -0.13 | -0.14 | -7.7% |
| 2025-03-11 | -0.17 | -0.13 | +22.2% |
| 2024-11-12 | -0.23 | -0.20 | +11.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $733.0K | -88.3% |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $718.0K | – |
| 2025-09-30 | $132.0K | – |
| 2025-06-30 | $6.3M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Stats refreshed 2026-10-21 11:27:07 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026